Presented at #ESMO2026 –

The Lancet· @TheLancet · X·2026-10-26 20:50· 5 小时前评分70

正文 · 机器翻译

在 #ESMO2026 上报告 –

Izalontamab brengitecan 对比含铂化疗，用于EGFR突变型晚期非鳞状非小细胞肺癌患者在接受第三代EGFR酪氨酸激酶抑制剂治疗后进展（PANKU-Lung01）：一项在中国开展的多中心、随机、开放标签的3期试验 http://spkl.io/60147kgwO

1377 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

2575PNCT06838273 NCT06838273 NCT06838273按 NSCLC, locally advanced 对上

Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://esmocongress.esmo.org

LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

来源：The Lancet · x.com